Skip to main content

Table 1 Baseline data of the study participants

From: Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial

 

CBD (n = 23)

TA (n = 22)

Placebo (n = 24)

p

Age (years), mean (SD)

36.7 (11.3)

35.9 (10.4)

33.0 (10.1)

0.410a

Sex

 Male, n (%)

2 (2.9)

4 (5.8)

7 (10.2)

0.199b

 Female, n (%)

21 (30.4)

18 (26.1)

17 (24.6)

Duration of the ulcer (hours), mean (SD)

42.8 (10.5)

35.1 (13.6)

34.7 (13.0)

0.039a,c

Pseudomembranous ulcer size on day 0 from the photograph (mm2), mean (SD)

6.0 (3.9)

7.2 (4.9)

6.5 (5.0)

0.755a

Erythematous border size on day 0 from the photograph (mm2), mean (SD)

15.3 (8.9)

17.7 (11.9)

19.0 (20.3)

0.876a

VAS on day 0 (mm), mean (SD)

53.7 (19.6)

50.2 (23.7)

53.2 (25.7)

0.861d

USS (scores), mean (SD)

16.3 (4.3)

17.6 (4.6)

19.3 (4.1)

0.066d

OHIP-14 score at the first visit (scores), mean (SD)

25.1 (9.4)

24.7 (9.8)

30.5 (11.9)

0.110d

  1. ap-Values from the Kruskal–Wallis test
  2. bp-Values from the Pearson’s chi-square test
  3. cAfter adjusting the data with the Bonferroni correction for multiple tests, the difference was no longer significant (placebo-TA: p = 1.000, placebo-CBD: p = 0.070, TA-CBD: p = 0.099)
  4. dp-Values from one-way ANOVA